Overview of Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.

Anacor’s mission is to improve healthcare through unconventional thinking.

Anacor’s objective is to discover, develop and commercialize proprietary boron-based drug compounds with superior efficacy, safety and convenience for the treatment of a variety of diseases.

Anacor’s first approved drug, KERYDIN® () topical solution, 5%, is an oxaborole antifungal approved by the U.S. Food and Drug Administration in July 2014 for the topical treatment of of the toenails.

• Anacor entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which PharmaDerm, the branded dermatology division of Sandoz, distributes and commercializes KERYDIN in the United States.

Crisaborole Topical Ointment, 2%, is Anacor’s lead topical anti-inflammatory product candidate for the treatment of and , chronic inflammatory diseases that affect millions of people worldwide.

• If approved, crisaborole would be the first topical non-steroidal treatment that inhibits TNF-alpha release.

• Anacor completed enrollment in two pivotal Phase 3 clinical trials of Crisaborole Topical Ointment, 2%, in patients with mild-to-moderate atopic dermatitis. The company to expects to announce data from the two trials in 3Q 2015.

Ticker Symbol ANAC

Market Cap 3.44 billion

IPO November 24, 2010

# of Products in Development 4

# of Employees 100

Founded 2002

Headquarters Palo Alto, Calif.

Developing Small-Molecule Therapeutics Derived From Our Boron Chemistry Platform

Developing Small-Molecule Therapeutics Derived From Our Boron Chemistry Platform Anacor Pharmaceuticals Inc. | 1020 East Meadow Circle, Palo Alto, CA 94303-4230 | Anacor.com